When combined with SLC38A2, HCC cells became insensitive to GPNA treatment, suggesting that in HCC, SLC38A2 is a major target of GPNA despite being able to act on other glutamine transporters. This evidence concerns the gene SLC38A2 and hepatocellular carcinoma.